Fundz
You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →

Matisse Pharmaceuticals closed a €14 million Series A financing round to advance isupartob sodium through Phase 2 clinical development.

PRIVATESep 17, 2026•about 3 hours ago

Amount Raised

€14 Million

Round Type

Series A

LimburgBiotechnologyHealth CareTherapeuticsPharmaceutical

Investors

LiofBrightlands Venture Partners

Description

Matisse Pharmaceuticals B.V. has successfully completed its Series A financing round. The €14 million round was led by existing and new shareholders, including Brightlands Venture Partners and LIOF. The proceeds will be used for the Phase 2 clinical trial of isupartob sodium

Company Information

Company

Matisse Pharmaceuticals B.V

Location

Limburg, Netherlands

About

Matisse Pharmaceuticals B.V. is a clinical stage company founded in 2014 in Geleen, the Netherlands. The company is focused on developing safe and innovative therapies for disease indications characterized by elevated levels of circulating cytotoxic histones, including sepsis. Matisse Pharmaceuticals aims to address significant unmet medical needs in critical care through its novel therapeutic, isupartob sodium.

Don't miss Matisse Pharmaceuticals B.V's next move

Get an email the moment Matisse Pharmaceuticals B.V raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Matisse Pharmaceuticals B.V's next move

See what Strategic adds

Funding Insights

Based on industry data
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Matisse Pharmaceuticals B.V raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.